-
Exelixis' Cabozantinib Gets Breakthrough Therapy Status In Differentiated Thyroid Cancer
Thursday, February 25, 2021 - 12:11pm | 188Read More...The FDA has granted Breakthrough Therapy Designation to Exelixis Inc's (NASDAQ: EXEL) CABOMETYX cabozantinib as a potential treatment for patients with differentiated thyroid cancer progressed following prior therapy and are radioactive iodine-refractory. The company...
-
Celator Surges 70% After Acquisition Announcement By Jazz Pharmaceuticals
Tuesday, May 31, 2016 - 8:28am | 364Read More...Shares of Celator Pharmaceuticals Inc (NASDAQ: CPXX) surged higher by more than 70 percent early Tuesday morning after the company has agreed to be acquired by Jazz Pharmaceuticals plc (NASDAQ: JAZZ) for approximately $1.5 billion, or $30.25 per share. Celator's stock closed for trading at...
